Leukemia Clinical Trial
Official title:
Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth
in different ways. Some block the ability of cancer cells to grow and spread. Others find
cancer cells and help kill them or carry cancer-killing substances to them.
Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in
bone marrow or peripheral blood. Giving monoclonal antibody therapy together with GM-CSF may
be an effective treatment for early-stage chronic lymphocytic leukemia.
PURPOSE: This phase II trial is studying the side effects of giving rituximab and alemtuzumab
together with GM-CSF and to see how well it works in treating patients with early-stage
chronic lymphocytic leukemia.
OBJECTIVES:
Primary
- To assess the rate of complete and overall response in patients with high-risk,
early-stage, chronic lymphocytic leukemia (CLL) treated with alemtuzumab, rituximab, and
sargramostim (GM-CSF).
- To monitor and assess toxicity of this regimen in these patients through clinical
evaluation and serial monitoring of cytomegalovirus antigenemia by polymerase chain
reaction (PCR).
Secondary
- To determine the overall and progression-free survival, time to response, time to next
treatment, and duration of response in patients treated with this regimen.
- To assess the correlation between individual prognostic markers (i.e., 17p-, 11q-,
unmutated VH gene, use of VH3-21, ZAP70+, CD38+) and clinical outcome.
Correlative Studies
- To assess response in these patients using an expanded definition of response, including
minimal residual disease (MRD) by sensitive flow cytometry in patients in complete
clinical remission.
- To assess MRD status of responding patients using sensitive flow cytometry and molecular
assays (i.e., spectral karyotype analysis of CLL cells) before treatment and at relapse
to identify subpopulations that could contribute to disease resistance and relapse.
- To detail the in vivo effect of this regimen on critical aspects of the immune system in
CLL.
- To determine if GM-CSF, β-glucan, and CpG7909 can increase antibody dependent cellular
cytotoxicity to improve efficacy against CLL cells and clinical response to treatment.
OUTLINE: Patients receive rituximab IV over 30 minutes on day 3 of weeks 2-5, alemtuzumab
subcutaneously (SC) on days 3, 4, and 5 in week 1 and on days 1, 3, and 5 in weeks 2-5, and
sargramostim SC on days 1, 3, and 5 in weeks 1-6. Treatment continues in the absence of
disease progression or unacceptable toxicity.
Patients undergo blood sample collection for measurement of serum cytomegalovirus DNA copy
number by polymerase chain reaction at baseline, weekly during treatment, and monthly for the
6 months after completion of treatment. Patients also undergo bone marrow biopsy and aspirate
at two months and then again at 12 months (if in complete remission). Blood samples are
collected periodically during study for evaluation of prognostic biomarkers (i.e., 11q-,
17p-, unmutated IgVH gene, VH3-21 gene segment use, and CD38 and ZAP-70 expression) by
fluorescent in situ hybridization (FISH) and for immunophenotyping by flow cytometry. Blood
samples are collected from patients at the Mayo Clinic Rochester site at baseline and
periodically during study for immunological and other correlative studies, including minimal
residual disease (in responding patients only).
After completion of study therapy, patients are followed periodically for up to 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |